200 related articles for article (PubMed ID: 30141252)
21. Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy.
Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hirooka Y; Toyoda H; Kumada T; Hattori M; Katano Y; Goto H
J Viral Hepat; 2018 Dec; 25(12):1446-1451. PubMed ID: 29993164
[TBL] [Abstract][Full Text] [Related]
22. Fitness-associated substitutions following failure of direct-acting antivirals assessed by deep sequencing of full-length hepatitis C virus genomes.
Fourati S; Rodriguez C; Soulier A; Donati F; Hamadat S; Poiteau L; Demontant V; Brillet R; Ahnou N; Gricourt G; Chevaliez S; Ahmed-Belkacem A; Pawlotsky JM
Aliment Pharmacol Ther; 2020 Nov; 52(10):1583-1591. PubMed ID: 32886807
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.
Bartels DJ; Sullivan JC; Zhang EZ; Tigges AM; Dorrian JL; De Meyer S; Takemoto D; Dondero E; Kwong AD; Picchio G; Kieffer TL
J Virol; 2013 Feb; 87(3):1544-53. PubMed ID: 23152524
[TBL] [Abstract][Full Text] [Related]
24. Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment.
Kai Y; Hikita H; Morishita N; Murai K; Nakabori T; Iio S; Hagiwara H; Imai Y; Tamura S; Tsutsui S; Naito M; Nishiuchi M; Kondo Y; Kato T; Suemizu H; Yamada R; Oze T; Yakushijin T; Hiramatsu N; Sakamori R; Tatsumi T; Takehara T
Sci Rep; 2017 Jan; 7():41660. PubMed ID: 28134353
[TBL] [Abstract][Full Text] [Related]
25. Ultrasensitive HCV RNA Quantification in Antiviral Triple Therapy: New Insight on Viral Clearance Dynamics and Treatment Outcome Predictors.
Garbuglia AR; Visco-Comandini U; Lionetti R; Lapa D; Castiglione F; D'Offizi G; Taibi C; Montalbano M; Capobianchi MR; Paci P
PLoS One; 2016; 11(8):e0158989. PubMed ID: 27560794
[TBL] [Abstract][Full Text] [Related]
26. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
[TBL] [Abstract][Full Text] [Related]
27. Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antivirals.
Liu CH; Chang YP; Lee JY; Chen CY; Kao WY; Lin CL; Yang SS; Shih YL; Peng CY; Lee FJ; Tsai MC; Huang SC; Su TH; Tseng TC; Liu CJ; Chen PJ; Kao JH
J Med Virol; 2024 May; 96(5):e29675. PubMed ID: 38746997
[TBL] [Abstract][Full Text] [Related]
28. NS5A resistance - associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey.
Sayan M; Yıldırım FS; Akhan S; Yıldırım AA; Şirin G; Cabalak M; Demir M; Can S; Ersöz G; Altıntaş E; Ensaroğlu F; Akbulut A; Şener A; Deveci A
Int J Infect Dis; 2020 Jun; 95():84-89. PubMed ID: 32302766
[TBL] [Abstract][Full Text] [Related]
29. Pooled Prevalence of NS5A Resistance-Associated Substitutions in Chronic HCV Genotype 3 Infection: A Study Based on Deposited Sequences in GenBank.
Sharafi H; Ghalamkari S; Hassanshahi A; Alavian SM
Microb Drug Resist; 2019 Sep; 25(7):1072-1079. PubMed ID: 31021305
[TBL] [Abstract][Full Text] [Related]
30. Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.
Takeda H; Ueda Y; Inuzuka T; Yamashita Y; Osaki Y; Nasu A; Umeda M; Takemura R; Seno H; Sekine A; Marusawa H
Sci Rep; 2017 Mar; 7():45605. PubMed ID: 28361915
[TBL] [Abstract][Full Text] [Related]
31. HCV NS3 quasispecies in liver and plasma and dynamics of telaprevir-resistant variants in breakthrough patients assessed by UDPS: A case study.
Bartolini B; Selleri M; Garbuglia AR; Giombini E; Taibi C; Lionetti R; D'Offizi G; Capobianchi MR
J Clin Virol; 2015 Nov; 72():60-5. PubMed ID: 26418073
[TBL] [Abstract][Full Text] [Related]
32. Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives.
Harrington PR; Komatsu TE; Deming DJ; Donaldson EF; O'Rear JJ; Naeger LK
Hepatology; 2018 Jun; 67(6):2430-2448. PubMed ID: 29194682
[TBL] [Abstract][Full Text] [Related]
33. Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study.
Cento V; Aragri M; Teti E; Polilli E; Bertoli A; Foroghi L; Barbaliscia S; Di Maio VC; Pieri A; Pace Palitti V; Sarmati L; Parruti G; Andreoni M; Perno CF; Ceccherini-Silberstein F
J Antimicrob Chemother; 2017 Dec; 72(12):3420-3424. PubMed ID: 28961921
[TBL] [Abstract][Full Text] [Related]
34. Natural prevalence of NS3 gene resistance-associated substitutions (RASs) in patients with chronic hepatitis C from the state of Pará/Brazil.
da Silva DL; Nunes HM; Freitas PEB
Virus Res; 2021 Jan; 292():198251. PubMed ID: 33259871
[TBL] [Abstract][Full Text] [Related]
35. NS3 Variability in Hepatitis C Virus Genotype 1A Isolates from Liver Tissue and Serum Samples of Treatment-Naïve Patients with Chronic Hepatitis C.
D'Aliberti D; Cacciola I; Musolino C; Raffa G; Filomia R; Alibrandi A; Benfatto S; Beninati C; Saitta C; Giosa D; Romeo O; Raimondo G; Pollicino T
Intervirology; 2018; 61(1):1-8. PubMed ID: 30021203
[TBL] [Abstract][Full Text] [Related]
36. Significance of detectable HCV RNA below the limit of quantification in patients treated with DAAs using standard and ultrasensitive protocols.
Visco-Comandini U; Lapa D; Lionetti R; Taibi C; Loiacono L; Montalbano M; Capobianchi MR; D'Offizi G; Garbuglia AR
J Med Virol; 2018 Jul; 90(7):1264-1271. PubMed ID: 29611880
[TBL] [Abstract][Full Text] [Related]
37. Prediction of virologic response in difficult-to-treat chronic hepatitis C patients during high-dose interferon induction therapy.
Gelderblom HC; Zaaijer HL; Dijkgraaf MG; Van Der Meer J; Weegink CJ; Jansen PL; Beld MG; Reesink HW
Scand J Gastroenterol; 2008; 43(7):857-69. PubMed ID: 18584525
[TBL] [Abstract][Full Text] [Related]
38. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
39. Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.
Miyasaka A; Kumagai I; Abe K; Suzuki K
Hepatogastroenterology; 2012 May; 59(115):794-9. PubMed ID: 22020909
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of
Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
